Intuitive Surgical, Inc. (ISRG)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Intuitive Surgical, Inc. (ISRG) trades at $473.76 with AI Score 56/100 (Hold). Intuitive Surgical is the global leader in robotic-assisted surgery, driven by its da Vinci Surgical System and Ion endoluminal system. Market cap: $168.25B, Sector: Healthcare.
Last analyzed: Feb 9, 2026Intuitive Surgical, Inc. (ISRG) Healthcare & Pipeline Overview
Intuitive Surgical pioneers robotic-assisted surgery with its da Vinci and Ion systems, offering minimally invasive solutions globally. With a strong installed base, recurring revenue model, and a commitment to innovation, Intuitive Surgical is transforming healthcare and driving shareholder value.
Investment Thesis
Intuitive Surgical presents a notable research candidate due to its dominant market share in robotic-assisted surgery and its recurring revenue model. The company's da Vinci Surgical System has become a standard of care in many surgical specialties, driving consistent demand for instruments, accessories, and services. With a gross margin of 66.1% and a profit margin of 28.4%, Intuitive Surgical demonstrates strong profitability. Growth catalysts include expanding applications of the da Vinci system, increasing adoption of the Ion endoluminal system, and geographic expansion into emerging markets. The company's commitment to innovation and its strong balance sheet position it for long-term growth and value creation. The current P/E ratio is 60.66.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $173.36 billion reflects investor confidence in Intuitive Surgical's market leadership and growth potential.
- Profit margin of 28.4% showcases the company's efficient operations and pricing power.
- Gross margin of 66.1% indicates the high value and differentiation of Intuitive Surgical's products and services.
- The da Vinci Surgical System has a large and growing installed base, driving recurring revenue from instruments, accessories, and services.
- Intuitive Surgical's commitment to innovation and clinical research supports the development of new applications and technologies.
Competitors & Peers
Strengths
- Dominant market share in surgical robotics.
- Strong recurring revenue model.
- High gross and profit margins.
- Extensive installed base of da Vinci systems.
Weaknesses
- High cost of da Vinci systems may limit adoption in some markets.
- Dependence on regulatory approvals for new products and applications.
- Competition from established medical device companies.
Catalysts
- FDA approval for new da Vinci system features and applications.
- Increasing adoption of the Ion endoluminal system for lung biopsies.
- Expansion into new geographic markets, particularly in Asia.
- Development and launch of new surgical instruments and accessories.
Risks
- Product recalls or safety concerns could damage the company's reputation.
- Increased competition from other surgical robotics companies.
- Changes in healthcare regulations or reimbursement policies could impact sales.
- Economic downturn could reduce hospital capital spending.
- Intellectual property disputes could limit the company's ability to protect its technology.
Growth Opportunities
- Expanding Surgical Applications: Intuitive Surgical has the opportunity to expand the applications of the da Vinci system into new surgical specialties, such as general surgery, thoracic surgery, and colorectal surgery. Each new application represents a significant market opportunity, as it allows the company to reach a broader range of surgeons and patients. The market size for these new applications is estimated to be billions of dollars, and Intuitive Surgical is investing in clinical research and development to support their adoption. Timeline: Ongoing.
- Increasing Adoption of Ion Endoluminal System: The Ion endoluminal system offers a significant growth opportunity for Intuitive Surgical in the diagnostic space. This system enables minimally invasive biopsies in the lung, providing a valuable tool for diagnosing lung cancer and other respiratory diseases. The market for lung biopsies is estimated to be substantial, and Intuitive Surgical is focused on increasing awareness and adoption of the Ion system among pulmonologists and hospitals. Timeline: Ongoing.
- Geographic Expansion: Intuitive Surgical has significant growth opportunities in international markets, particularly in Asia and Europe. These markets are experiencing rapid growth in healthcare spending and increasing demand for advanced surgical technologies. Intuitive Surgical is investing in expanding its sales and marketing presence in these regions, as well as developing partnerships with local hospitals and healthcare providers. Timeline: Ongoing.
- Development of New Technologies: Intuitive Surgical is committed to innovation and is continuously investing in the development of new technologies for robotic-assisted surgery. These technologies include advanced imaging systems, surgical instruments, and software applications. The company's R&D efforts are focused on improving the precision, safety, and efficiency of surgical procedures, as well as expanding the capabilities of the da Vinci system. Timeline: Ongoing.
- Integrated Digital Solutions: Intuitive Surgical is developing integrated digital solutions that connect surgeons, hospitals, and patients, providing valuable data and insights to improve surgical outcomes. These solutions include data analytics platforms, remote collaboration tools, and patient engagement applications. The market for digital surgery solutions is growing rapidly, and Intuitive Surgical is well-positioned to capitalize on this trend. Timeline: Ongoing.
Opportunities
- Expanding applications of da Vinci system into new surgical specialties.
- Increasing adoption of Ion endoluminal system.
- Geographic expansion into emerging markets.
- Development of new technologies and digital solutions.
Threats
- Technological disruption from new entrants.
- Pricing pressure from competitors.
- Changes in healthcare regulations and reimbursement policies.
- Product liability claims.
Competitive Advantages
- Technological leadership in surgical robotics.
- Strong brand reputation and established relationships with surgeons.
- High switching costs for hospitals due to investment in da Vinci systems and training.
- Extensive patent portfolio protecting its technology.
- Large and growing installed base driving recurring revenue.
About ISRG
Intuitive Surgical, Inc., founded in 1995 and headquartered in Sunnyvale, California, is at the forefront of surgical robotics. The company designs, manufactures, and markets the da Vinci Surgical System, a revolutionary platform that enables surgeons to perform complex procedures through small incisions with enhanced precision, dexterity, and control. This minimally invasive approach leads to reduced patient trauma, faster recovery times, and improved clinical outcomes. Beyond surgery, Intuitive Surgical has expanded into diagnostic procedures with the Ion endoluminal system, enabling minimally invasive biopsies in the lung. The company's comprehensive ecosystem includes a wide range of stapling, energy, and core instrumentation tailored for its surgical systems. Intuitive Surgical also provides extensive training and education programs for surgeons and healthcare professionals, ensuring optimal utilization of its technology. Furthermore, the company offers a suite of services, including installation, repair, and maintenance, to support its growing installed base of da Vinci systems worldwide. Integrated digital capabilities provide unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. Intuitive Surgical's global presence and commitment to innovation have solidified its position as the dominant player in the surgical robotics market.
What They Do
- Develops and manufactures the da Vinci Surgical System.
- Markets the da Vinci Surgical System globally.
- Offers the Ion endoluminal system for minimally invasive lung biopsies.
- Provides a range of instruments and accessories for its surgical systems.
- Delivers training and education programs for surgeons and healthcare professionals.
- Offers support, installation, repair, and maintenance services.
- Develops integrated digital capabilities for hospitals.
Business Model
- Sales of da Vinci Surgical Systems to hospitals and surgical centers.
- Recurring revenue from sales of instruments, accessories, and services.
- Training and education programs for surgeons and healthcare professionals.
- Service contracts for maintenance and repair of da Vinci systems.
Industry Context
Intuitive Surgical operates in the rapidly growing medical instruments and supplies industry, driven by increasing demand for minimally invasive surgery and advancements in robotic technology. The global surgical robotics market is expected to continue to expand, fueled by an aging population, rising healthcare expenditures, and a growing preference for less invasive procedures. While Intuitive Surgical holds a dominant position, competitors such as BAX, BDX, BNGO, COO, and EMBC are also vying for market share. The industry is characterized by high barriers to entry, including regulatory approvals, technological expertise, and established relationships with surgeons and hospitals.
Key Customers
- Hospitals and surgical centers.
- Surgeons and surgical teams.
- Patients undergoing minimally invasive surgery.
- Pulmonologists performing lung biopsies.
Financials
Chart & Info
Intuitive Surgical, Inc. (ISRG) stock price: $473.76 (-1.96, -0.41%)
Latest News
-
Grove Bank & Trust Increases Stock Holdings in Intuitive Surgical, Inc. $ISRG
defenseworld.net · Mar 22, 2026
-
2 Defensive Healthcare Stocks to Buy Right Now
fool.com · Mar 22, 2026
-
Is Intuitive Surgical, Inc. (ISRG) A Good Stock To Buy Now?
Yahoo! Finance: ISRG News · Mar 21, 2026
-
Jim Cramer on Intuitive Surgical: “It’s Just Gotten Too Expensive Per Share”
Yahoo! Finance: ISRG News · Mar 21, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ISRG.
Price Targets
Consensus target: $660.73
MoonshotScore
What does this score mean?
The MoonshotScore rates ISRG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Grove Bank & Trust Increases Stock Holdings in Intuitive Surgical, Inc. $ISRG
2 Defensive Healthcare Stocks to Buy Right Now
Is Intuitive Surgical, Inc. (ISRG) A Good Stock To Buy Now?
Jim Cramer on Intuitive Surgical: “It’s Just Gotten Too Expensive Per Share”
Related Investment Themes
Intuitive Surgical, Inc. Healthcare Stock: Key Questions Answered
What does Intuitive Surgical, Inc. do?
Intuitive Surgical is the global leader in robotic-assisted surgery. The company designs, manufactures, and markets the da Vinci Surgical System and the Ion endoluminal system. The da Vinci system enables surgeons to perform complex procedures through small incisions with enhanced precision and control. The Ion system enables minimally invasive biopsies in the lung. Intuitive Surgical also provides a range of instruments, accessories, and services to support its surgical systems. The company's business model is based on selling da Vinci systems and generating recurring revenue from instruments, accessories, and services.
Is ISRG stock worth researching?
ISRG stock may be worth researching for investors seeking long-term growth potential in the healthcare sector. The company has a dominant market share in surgical robotics, a strong recurring revenue model, and a history of innovation. However, the stock's high valuation (P/E of 60.66) reflects these strengths and may limit near-term upside. Investors may want to evaluate the company's growth catalysts, such as expanding applications of the da Vinci system and geographic expansion, as well as potential risks, such as increased competition and changes in healthcare regulations.
What are the main risks for ISRG?
The main risks for Intuitive Surgical include increased competition from other surgical robotics companies, changes in healthcare regulations and reimbursement policies, product liability claims, and technological disruption. The company also faces the risk of economic downturn, which could reduce hospital capital spending. Additionally, intellectual property disputes could limit the company's ability to protect its technology. These risks could negatively impact the company's sales, profitability, and stock price.
What are the key factors to evaluate for ISRG?
Intuitive Surgical, Inc. (ISRG) currently holds an AI score of 56/100, indicating moderate score. The stock trades at a P/E of 59.4x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Analysts target $660.73 (+39% from $473.76). Key strength: Dominant market share in surgical robotics. Primary risk to monitor: Product recalls or safety concerns could damage the company's reputation. This is not financial advice.
How frequently does ISRG data refresh on this page?
ISRG prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ISRG's recent stock price performance?
Recent price movement in Intuitive Surgical, Inc. (ISRG) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $660.73 implies 39% upside from here. Notable catalyst: Dominant market share in surgical robotics. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ISRG overvalued or undervalued right now?
Determining whether Intuitive Surgical, Inc. (ISRG) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 59.4. Analysts target $660.73 (+39% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ISRG?
Before investing in Intuitive Surgical, Inc. (ISRG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.